<p>再生元制药（NASDAQ:REGN - 获取免费报告）在周三发布的一份报告中，摩根士丹利的研究分析师将其目标价格从 788.00 美元下调至 730.00 美元，Benzinga 报道。该券商目前对这家生物制药公司的股票给予 “持平” 评级。摩根士丹利的目标价格意味着该公司股价有 9.83% 的潜在上涨空间。</p>
<ul>
<li>Amylyx 股票：为何完整的产品线故事至关重要</li>
</ul>
<p>REGN 曾是多份研究报告的主题。Weiss Ratings 在 6 月 24 日的研究报告中重申了对再生元制药股票的 “持有（c）” 评级。Sanford C. Bernstein 在 4 月 8 日的研究报告中将再生元制药的目标价格从 925.00 美元下调至 921.00 美元，并对该股票给予 “跑赢大盘” 评级。华尔街 Zen 在周六的报告中将再生元制药的股票评级从 “买入” 下调至 “持有”。摩根大通在 5 月 18 日的研究报告中将再生元制药的目标价格从 950.00 美元下调至 850.00 美元，并对该公司给予 “增持” 评级。最后，Piper Sandler 在 5 月 18 日的报告中将再生元制药的目标价格从 875.00 美元下调至 855.00 美元，并对该股票给予 “增持” 评级。一位股票研究分析师对该股票给予了强烈买入评级，十七位分析师给予买入评级，九位分析师给予持有评级。根据 MarketBeat 的数据，再生元制药目前的平均评级为 “适度买入”，共识目标价格为 787.71 美元。</p>
<p><strong>查看我们对再生元制药的最新分析</strong></p>
<h2>再生元制药的价格表现</h2>
<ul>
<li>Ozempic、Mounjaro、Wegovy 或 Zepbound？该 ETF 包含它们所有</li>
</ul>
<p>周三中午交易时，NASDAQ REGN 的股票下跌了 11.57 美元，达到 664.66 美元。该公司的交易量为 257,618 股，而其平均交易量为 867,924 股。该公司的债务与股本比率为 0.06，流动比率为 3.57，速动比率为 2.96。再生元制药的 52 周低点为 541.00 美元，52 周高点为 821.11 美元。该股票的 50 日移动平均线为 648.64 美元，200 日移动平均线为 724.11 美元。该公司的市值为 702.7 亿美元，市盈率为 16.18，市盈增长比率为 1.43，贝塔值为 0.24。</p>
<p>再生元制药（NASDAQ:REGN - 获取免费报告）最近在 4 月 29 日发布了季度财报。这家生物制药公司报告的每股收益为 9.47 美元，超出分析师一致预期的 8.91 美元，超出幅度为 0.56 美元。再生元制药的股本回报率为 13.16%，净利润率为 29.65%。该公司季度收入为 36.1 亿美元，而分析师预期为 34.8 亿美元。在去年同期，该公司每股收益为 8.22 美元。与去年同期相比，该公司的收入增长了 19.0%。整体来看，卖方分析师预计再生元制药在当前财年的每股收益将达到 37.46 美元。</p>
<h2>再生元制药的内部买卖情况</h2>
<ul>
<li>辉瑞加大对减肥药的投资</li>
</ul>
<p>在其他消息中，董事 Arthur F. Ryan 在 7 月 2 日的交易中出售了 200 股公司的股票。股票以平均价格 650.15 美元出售，总价值为 130,030.00 美元。出售后，该董事直接持有公司 17,303 股，价值 11,249,545.45 美元。该交易在向 SEC 提交的文件中披露，文件可在 SEC 网站上获取。该交易是在预先安排的 10b5-1 交易计划下执行的。公司内部人士目前持有 6.97% 的股票。</p>
<h2>机构投资者对再生元制药的看法</h2>
<p>大型投资者最近增加或减少了对该股票的持股。Insigneo Advisory Services LLC 在第四季度将其在再生元制药的持股增加了 3.0%。Insigneo Advisory Services LLC 目前持有 445 股该生物制药公司的股票，价值 343,000 美元，在此期间又购买了 13 股。Arjuna Capital 在第一季度将其在再生元制药的持股增加了 3.2%。Arjuna Capital 目前持有 457 股该生物制药公司的股票，价值 353,000 美元，在上个季度又购买了 14 股。Guardian Wealth Advisors LLC NC 在第四季度将其在再生元制药的持股增加了 3.3%。Guardian Wealth Advisors LLC NC 目前持有 443 股该生物制药公司的股票，价值 342,000 美元，在此期间又购买了 14 股。TD Private Client Wealth LLC 在第四季度将其在再生元制药的持股增加了 9.7%。TD Private Client Wealth LLC 目前持有 169 股该生物制药公司的股票，价值 130,000 美元，在上个季度又购买了 15 股。最后，MCF Advisors LLC 在第四季度将其在再生元制药的持股增加了 50.0%。MCF Advisors LLC 目前持有 45 股该生物制药公司的股票，价值 35,000 美元，在此期间又购买了 15 股。83.31% 的股票由机构投资者持有。</p>
<h2>影响再生元制药的关键故事</h2>
<p>以下是本周影响再生元制药的关键新闻故事：</p>
<ul>
<li>积极情绪：Benchmark 将 Regeneron 的评级从持有上调至 <strong>买入</strong>，这可能会增强投资者对该股票短期前景的信心。Regeneron Pharmaceuticals NASDAQ: REGN 的评级在 Benchmark 上调至买入</li>
<li>积极情绪：Truist 重申 <strong>买入</strong> 评级，并设定 769 美元的目标价，暗示分析师仍然看到显著的上涨空间。Regeneron Pharmaceuticals 的目标价被 Truist Financial Corporation 下调</li>
<li>积极情绪：尽管 HSBC 下调了目标价，但仍维持 <strong>买入</strong> 评级，表明对 Regeneron 基本面的持续信心。Regeneron Pharmaceuticals 的目标价被 HSBC Holdings plc 下调</li>
<li>积极情绪：Zacks 将 Regeneron 确定为强劲的价值股票，并指出其有利的盈利意外历史，这可能支持对下一个报告的乐观情绪。以下是 Regeneron (REGN) 是强劲价值股票的原因</li>
<li>中性情绪：加拿大皇家银行将目标价下调至 696 美元，并维持 <strong>行业表现</strong> 评级，这是一个谨慎的更新，但仍指向适度的上涨空间。Regeneron Pharmaceuticals 的目标价被加拿大皇家银行下调</li>
<li>中性情绪：更广泛的生物技术乐观情绪，包括对该行业可能成为 “市场上最热门的群体” 的评论，可能在帮助情绪，尽管这并非特指 Regeneron。吉姆·克莱默称生物技术为 “市场上最热门的群体”</li>
<li>消极情绪：董事 Arthur F. Ryan 在预先安排的 10b5-1 计划中出售了 200 股，这一小规模的内部交易可能仍会抑制情绪。董事出售的 SEC 文件</li>
</ul>
<h2>关于 Regeneron Pharmaceuticals</h2>
<p>(获取免费报告)</p>
<p>Regeneron Pharmaceuticals, Inc NASDAQ: REGN 是一家总部位于纽约塔里敦的美国生物技术公司，成立于 1988 年。该公司专注于发现、开发、生产和商业化用于治疗严重医疗状况的药物。公司结合实验室研究、临床开发和内部生产，推进多个治疗领域的生物治疗管线。</p>
<p>Regeneron 以其专有的药物发现技术而闻名，包括其 VelocImmune 平台，该平台用于生成完全人源的单克隆抗体。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过 Regeneron Pharmaceuticals</li>
<li>市场刚刚动荡——这三只 ETF 可能会更强劲</li>
<li>Meta Platforms 的云计算推动：增长机会与 AI 担忧</li>
<li>为什么 Penguin Solutions 可能是最聪明的 AI 基础设施股票</li>
<li>想在 IPO 前接触 Anthropic？这两家 AI 巨头已经在其中</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Regeneron Pharmaceuticals 吗？</h2>
<p>在考虑 Regeneron Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Regeneron Pharmaceuticals 并不在名单上。</p>
<p>虽然 Regeneron Pharmaceuticals 目前在分析师中获得中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

再生元制药

<p>摩根士丹利将再生元制药（REGN）的目标股价从 788.00 美元下调至 730.00 美元，并给予 “持平” 评级。这一调整是在其他分析师的行动之后，包括摩根大通、派珀·桑德勒和华尔街禅的评级下调和目标下调。尽管下调后的目标显示出约 9.8% 的上涨空间，但 REGN 的股价在午盘时段下跌。该公司最近公布了强劲的季度财报，超出了每股收益和收入的预期</p>

<p>Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) had its target price decreased by research analysts at Morgan Stanley from $788.00 to $730.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has an &#34;equal weight&#34; rating on the biopharmaceutical company's stock. Morgan Stanley's price target would indicate a potential upside of 9.83% from the company's previous close.</p>
<div class="lb-trans"><p>再生元制药（NASDAQ:REGN - 获取免费报告）在周三发布的一份报告中，摩根士丹利的研究分析师将其目标价格从 788.00 美元下调至 730.00 美元，Benzinga 报道。该券商目前对这家生物制药公司的股票给予 “持平” 评级。摩根士丹利的目标价格意味着该公司股价有 9.83% 的潜在上涨空间。</p>
</div><ul>
<li>Amylyx Stock: Why the Full Pipeline Story Matters</li>
</ul>
<div class="lb-trans"><ul>
<li>Amylyx 股票：为何完整的产品线故事至关重要</li>
</ul>
</div><p>REGN has been the subject of a number of other research reports. Weiss Ratings restated a &#34;hold (c)&#34; rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 24th. Sanford C. Bernstein decreased their price target on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an &#34;outperform&#34; rating on the stock in a research note on Wednesday, April 8th. Wall Street Zen downgraded shares of Regeneron Pharmaceuticals from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Saturday. JPMorgan Chase &amp; Co. cut their price objective on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an &#34;overweight&#34; rating for the company in a research report on Monday, May 18th. Finally, Piper Sandler reduced their target price on Regeneron Pharmaceuticals from $875.00 to $855.00 and set an &#34;overweight&#34; rating on the stock in a report on Monday, May 18th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $787.71.</p>
<div class="lb-trans"><p>REGN 曾是多份研究报告的主题。Weiss Ratings 在 6 月 24 日的研究报告中重申了对再生元制药股票的 “持有（c）” 评级。Sanford C. Bernstein 在 4 月 8 日的研究报告中将再生元制药的目标价格从 925.00 美元下调至 921.00 美元，并对该股票给予 “跑赢大盘” 评级。华尔街 Zen 在周六的报告中将再生元制药的股票评级从 “买入” 下调至 “持有”。摩根大通在 5 月 18 日的研究报告中将再生元制药的目标价格从 950.00 美元下调至 850.00 美元，并对该公司给予 “增持” 评级。最后，Piper Sandler 在 5 月 18 日的报告中将再生元制药的目标价格从 875.00 美元下调至 855.00 美元，并对该股票给予 “增持” 评级。一位股票研究分析师对该股票给予了强烈买入评级，十七位分析师给予买入评级，九位分析师给予持有评级。根据 MarketBeat 的数据，再生元制药目前的平均评级为 “适度买入”，共识目标价格为 787.71 美元。</p>
</div><p><strong>View Our Latest Analysis on Regeneron Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我们对再生元制药的最新分析</strong></p>
</div><h2>Regeneron Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>再生元制药的价格表现</h2>
</div><ul>
<li>Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All</li>
</ul>
<div class="lb-trans"><ul>
<li>Ozempic、Mounjaro、Wegovy 或 Zepbound？该 ETF 包含它们所有</li>
</ul>
</div><p>Shares of NASDAQ REGN traded down $11.57 during mid-day trading on Wednesday, reaching $664.66. The company's stock had a trading volume of 257,618 shares, compared to its average volume of 867,924. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. Regeneron Pharmaceuticals has a 52 week low of $541.00 and a 52 week high of $821.11. The stock has a fifty day moving average of $648.64 and a two-hundred day moving average of $724.11. The firm has a market capitalization of $70.27 billion, a PE ratio of 16.18, a P/E/G ratio of 1.43 and a beta of 0.24.</p>
<div class="lb-trans"><p>周三中午交易时，NASDAQ REGN 的股票下跌了 11.57 美元，达到 664.66 美元。该公司的交易量为 257,618 股，而其平均交易量为 867,924 股。该公司的债务与股本比率为 0.06，流动比率为 3.57，速动比率为 2.96。再生元制药的 52 周低点为 541.00 美元，52 周高点为 821.11 美元。该股票的 50 日移动平均线为 648.64 美元，200 日移动平均线为 724.11 美元。该公司的市值为 702.7 亿美元，市盈率为 16.18，市盈增长比率为 1.43，贝塔值为 0.24。</p>
</div><p>Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, topping analysts' consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The company had revenue of $3.61 billion for the quarter, compared to analysts' expectations of $3.48 billion. During the same period in the previous year, the firm earned $8.22 EPS. The firm's revenue was up 19.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals will post 37.46 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>再生元制药（NASDAQ:REGN - 获取免费报告）最近在 4 月 29 日发布了季度财报。这家生物制药公司报告的每股收益为 9.47 美元，超出分析师一致预期的 8.91 美元，超出幅度为 0.56 美元。再生元制药的股本回报率为 13.16%，净利润率为 29.65%。该公司季度收入为 36.1 亿美元，而分析师预期为 34.8 亿美元。在去年同期，该公司每股收益为 8.22 美元。与去年同期相比，该公司的收入增长了 19.0%。整体来看，卖方分析师预计再生元制药在当前财年的每股收益将达到 37.46 美元。</p>
</div><h2>Insider Buying and Selling at Regeneron Pharmaceuticals</h2>
<div class="lb-trans"><h2>再生元制药的内部买卖情况</h2>
</div><ul>
<li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li>
</ul>
<div class="lb-trans"><ul>
<li>辉瑞加大对减肥药的投资</li>
</ul>
</div><p>In other news, Director Arthur F. Ryan sold 200 shares of the business's stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the sale, the director directly owned 17,303 shares in the company, valued at $11,249,545.45. The trade was a 1.14% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他消息中，董事 Arthur F. Ryan 在 7 月 2 日的交易中出售了 200 股公司的股票。股票以平均价格 650.15 美元出售，总价值为 130,030.00 美元。出售后，该董事直接持有公司 17,303 股，价值 11,249,545.45 美元。该交易在向 SEC 提交的文件中披露，文件可在 SEC 网站上获取。该交易是在预先安排的 10b5-1 交易计划下执行的。公司内部人士目前持有 6.97% 的股票。</p>
</div><h2>Institutional Investors Weigh In On Regeneron Pharmaceuticals</h2>
<div class="lb-trans"><h2>机构投资者对再生元制药的看法</h2>
</div><p>Large investors have recently added to or reduced their stakes in the stock. Insigneo Advisory Services LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 3.0% in the 4th quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company's stock worth $343,000 after purchasing an additional 13 shares during the period. Arjuna Capital lifted its position in Regeneron Pharmaceuticals by 3.2% in the first quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company's stock worth $353,000 after buying an additional 14 shares during the last quarter. Guardian Wealth Advisors LLC NC boosted its stake in Regeneron Pharmaceuticals by 3.3% during the fourth quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company's stock worth $342,000 after buying an additional 14 shares during the period. TD Private Client Wealth LLC increased its position in Regeneron Pharmaceuticals by 9.7% during the fourth quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company's stock valued at $130,000 after acquiring an additional 15 shares during the last quarter. Finally, MCF Advisors LLC raised its stake in shares of Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company's stock valued at $35,000 after acquiring an additional 15 shares during the period. 83.31% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>大型投资者最近增加或减少了对该股票的持股。Insigneo Advisory Services LLC 在第四季度将其在再生元制药的持股增加了 3.0%。Insigneo Advisory Services LLC 目前持有 445 股该生物制药公司的股票，价值 343,000 美元，在此期间又购买了 13 股。Arjuna Capital 在第一季度将其在再生元制药的持股增加了 3.2%。Arjuna Capital 目前持有 457 股该生物制药公司的股票，价值 353,000 美元，在上个季度又购买了 14 股。Guardian Wealth Advisors LLC NC 在第四季度将其在再生元制药的持股增加了 3.3%。Guardian Wealth Advisors LLC NC 目前持有 443 股该生物制药公司的股票，价值 342,000 美元，在此期间又购买了 14 股。TD Private Client Wealth LLC 在第四季度将其在再生元制药的持股增加了 9.7%。TD Private Client Wealth LLC 目前持有 169 股该生物制药公司的股票，价值 130,000 美元，在上个季度又购买了 15 股。最后，MCF Advisors LLC 在第四季度将其在再生元制药的持股增加了 50.0%。MCF Advisors LLC 目前持有 45 股该生物制药公司的股票，价值 35,000 美元，在此期间又购买了 15 股。83.31% 的股票由机构投资者持有。</p>
</div><h2>Key Stories Impacting Regeneron Pharmaceuticals</h2>
<div class="lb-trans"><h2>影响再生元制药的关键故事</h2>
</div><p>Here are the key news stories impacting Regeneron Pharmaceuticals this week:</p>
<div class="lb-trans"><p>以下是本周影响再生元制药的关键新闻故事：</p>
</div><ul>
<li>Positive Sentiment: Benchmark upgraded Regeneron to <strong>buy</strong> from hold, which can boost investor confidence in the stock’s near-term outlook. Regeneron Pharmaceuticals NASDAQ: REGN Rating Increased to Buy at Benchmark</li>
<li>Positive Sentiment: Truist reiterated a <strong>buy</strong> rating while setting a $769 price target, implying analysts still see meaningful upside. Regeneron Pharmaceuticals had its price target lowered by Truist Financial Corporation</li>
<li>Positive Sentiment: HSBC kept a <strong>buy</strong> rating even after lowering its price target, suggesting continued confidence in Regeneron’s fundamentals. Regeneron Pharmaceuticals had its price target lowered by HSBC Holdings plc</li>
<li>Positive Sentiment: Zacks highlighted Regeneron as a strong value stock with a favorable earnings surprise history, which may support optimism heading into the next report. Here's Why Regeneron (REGN) is a Strong Value Stock</li>
<li>Neutral Sentiment: Royal Bank of Canada cut its target to $696 and kept a <strong>sector perform</strong> rating, a cautious update that still points to modest upside. Regeneron Pharmaceuticals had its price target lowered by Royal Bank Of Canada</li>
<li>Neutral Sentiment: Broader biotech optimism, including comments that the sector could become “the hottest group in the market,” may be helping sentiment, though it is not Regeneron-specific. Jim Cramer Calls Biotech “The Hottest Group in the Market”</li>
<li>Negative Sentiment: Director Arthur F. Ryan sold 200 shares in a pre-arranged 10b5-1 plan, a small insider sale that may still dampen sentiment. SEC filing for director sale</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：Benchmark 将 Regeneron 的评级从持有上调至 <strong>买入</strong>，这可能会增强投资者对该股票短期前景的信心。Regeneron Pharmaceuticals NASDAQ: REGN 的评级在 Benchmark 上调至买入</li>
<li>积极情绪：Truist 重申 <strong>买入</strong> 评级，并设定 769 美元的目标价，暗示分析师仍然看到显著的上涨空间。Regeneron Pharmaceuticals 的目标价被 Truist Financial Corporation 下调</li>
<li>积极情绪：尽管 HSBC 下调了目标价，但仍维持 <strong>买入</strong> 评级，表明对 Regeneron 基本面的持续信心。Regeneron Pharmaceuticals 的目标价被 HSBC Holdings plc 下调</li>
<li>积极情绪：Zacks 将 Regeneron 确定为强劲的价值股票，并指出其有利的盈利意外历史，这可能支持对下一个报告的乐观情绪。以下是 Regeneron (REGN) 是强劲价值股票的原因</li>
<li>中性情绪：加拿大皇家银行将目标价下调至 696 美元，并维持 <strong>行业表现</strong> 评级，这是一个谨慎的更新，但仍指向适度的上涨空间。Regeneron Pharmaceuticals 的目标价被加拿大皇家银行下调</li>
<li>中性情绪：更广泛的生物技术乐观情绪，包括对该行业可能成为 “市场上最热门的群体” 的评论，可能在帮助情绪，尽管这并非特指 Regeneron。吉姆·克莱默称生物技术为 “市场上最热门的群体”</li>
<li>消极情绪：董事 Arthur F. Ryan 在预先安排的 10b5-1 计划中出售了 200 股，这一小规模的内部交易可能仍会抑制情绪。董事出售的 SEC 文件</li>
</ul>
</div><h2>About Regeneron Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Regeneron Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.</p>
<div class="lb-trans"><p>Regeneron Pharmaceuticals, Inc NASDAQ: REGN 是一家总部位于纽约塔里敦的美国生物技术公司，成立于 1988 年。该公司专注于发现、开发、生产和商业化用于治疗严重医疗状况的药物。公司结合实验室研究、临床开发和内部生产，推进多个治疗领域的生物治疗管线。</p>
</div><p>Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.</p>
<div class="lb-trans"><p>Regeneron 以其专有的药物发现技术而闻名，包括其 VelocImmune 平台，该平台用于生成完全人源的单克隆抗体。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Regeneron Pharmaceuticals</li>
<li>The Market Just Got Shaken—These 3 ETFs May Come Out Stronger</li>
<li>Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns</li>
<li>Why Penguin Solutions May Be the Smartest AI Infrastructure Stock</li>
<li>Want Anthropic Exposure Before the IPO? These 2 AI Giants Are Already There</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Regeneron Pharmaceuticals</li>
<li>市场刚刚动荡——这三只 ETF 可能会更强劲</li>
<li>Meta Platforms 的云计算推动：增长机会与 AI 担忧</li>
<li>为什么 Penguin Solutions 可能是最聪明的 AI 基础设施股票</li>
<li>想在 IPO 前接触 Anthropic？这两家 AI 巨头已经在其中</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=REGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Regeneron Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Regeneron Pharmaceuticals 吗？</h2>
</div><p>Before you consider Regeneron Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Regeneron Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Regeneron Pharmaceuticals 并不在名单上。</p>
</div><p>While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Regeneron Pharmaceuticals 目前在分析师中获得中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Lowered to $730.00 at Morgan Stanley

Market Beat

摩根士丹利

Amylyx Pharmaceuticals

摩根大通

Piper Sandler Cos

辉瑞

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

摩根士丹利将再生元制药（纳斯达克股票代码：REGN）的目标价下调至 730.00 美元